Suppr超能文献

多基因风险评分与 C 反应蛋白在预测冠心病事件中的比较。

Polygenic risk score in comparison with C-reactive protein for predicting incident coronary heart disease.

机构信息

Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University Medical Center, Nashville, TN, USA; Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

出版信息

Atherosclerosis. 2023 Aug;379:117194. doi: 10.1016/j.atherosclerosis.2023.117194. Epub 2023 Jul 26.

Abstract

BACKGROUND AND AIMS

Despite interest in the use of polygenic risk scores (PRS) for predicting coronary heart disease (CHD) risk, the clinical utility of PRS compared to conventional risk factors has not been demonstrated. We compared the performance of PRS with that of high-sensitivity C-reactive protein (hsCRP) in two well-established cohorts.

METHODS

The study population included individuals of European ancestry free of baseline CHD from ARIC (N = 13,113) and the Framingham Offspring Study (FHS) (N = 2,696). The primary predictors included a validated PRS consisting of >6.6 million single nucleotide polymorphisms and hsCRP. The outcome was incident CHD, defined as non-fatal or fatal myocardial infarction. We compared the performance of both predictors after adjusting for the Pooled Cohort Equations in multivariable-adjusted Cox regression models. We assessed discrimination and reclassification using c-statistics and net reclassification improvement.

RESULTS

Incident CHD occurred in 565 ARIC and 153 FHS participants. In multivariable-adjusted models, both PRS and hsCRP were associated with incident CHD (p < 0.05 in both cohorts). In models incorporating both predictors, strengths of association were similar. For instance, in ARIC, the hazard ratio per SD increment was 1.38 (95% CI, 1.27-1.50, p = 2.94 × 10) for PRS and 1.41 (1.30-1.55, p = 3.10 × 10) for hsCRP. Neither predictor significantly increased model discrimination or net reclassification when compared with models containing the Pooled Cohort Equations alone.

CONCLUSIONS

In two independent cohorts, PRS performed similarly to hsCRP for the prediction of CHD risk. These findings suggest PRS does not have unique clinical utility beyond this widely-available, inexpensive measure of risk in unselected middle-aged populations.

摘要

背景和目的

尽管人们对多基因风险评分(PRS)预测冠心病(CHD)风险的应用很感兴趣,但与传统危险因素相比,PRS 的临床实用性尚未得到证实。我们在两个成熟的队列中比较了 PRS 与高敏 C 反应蛋白(hsCRP)的性能。

方法

研究人群包括 ARIC(N=13113)和弗雷明汉后代研究(FHS)(N=2696)中无基线 CHD 的欧洲血统个体。主要预测指标包括一个由>660 万个单核苷酸多态性和 hsCRP 组成的经过验证的 PRS。结果是新发 CHD,定义为非致死性或致死性心肌梗死。我们在多变量调整 Cox 回归模型中调整了 Pooled Cohort Equations 后,比较了两种预测因子的性能。我们使用 c 统计量和净重新分类改善来评估区分度和重新分类。

结果

565 名 ARIC 和 153 名 FHS 参与者发生了 CHD 事件。在多变量调整模型中,PRS 和 hsCRP 均与 CHD 事件相关(两个队列中的 p 值均<0.05)。在包含两种预测因子的模型中,关联强度相似。例如,在 ARIC 中,PRS 每增加一个标准差的风险比为 1.38(95%CI,1.27-1.50,p=2.94×10),hsCRP 为 1.41(1.30-1.55,p=3.10×10)。与仅包含 Pooled Cohort Equations 的模型相比,这两种预测因子均未显著提高模型的区分度或净重新分类。

结论

在两个独立的队列中,PRS 对 CHD 风险的预测与 hsCRP 相似。这些发现表明,PRS 在未经选择的中年人群中,除了这种广泛可用且廉价的风险衡量标准外,其临床实用性并不独特。

相似文献

1
Polygenic risk score in comparison with C-reactive protein for predicting incident coronary heart disease.
Atherosclerosis. 2023 Aug;379:117194. doi: 10.1016/j.atherosclerosis.2023.117194. Epub 2023 Jul 26.
3
Predictive Utility of a Validated Polygenic Risk Score for Long-Term Risk of Coronary Heart Disease in Young and Middle-Aged Adults.
Circulation. 2022 Aug 23;146(8):587-596. doi: 10.1161/CIRCULATIONAHA.121.058426. Epub 2022 Jul 26.
4
Prognostic Value of a Polygenic Risk Score for Coronary Heart Disease in Individuals Aged 70 Years and Older.
Circ Genom Precis Med. 2022 Feb;15(1):e003429. doi: 10.1161/CIRCGEN.121.003429. Epub 2021 Dec 24.
5
Polygenic risk and incident coronary heart disease in a large multiethnic cohort.
Am J Prev Cardiol. 2024 Mar 28;18:100661. doi: 10.1016/j.ajpc.2024.100661. eCollection 2024 Jun.
7
8
Incremental Value of Polygenic Risk Scores in Primary Prevention of Coronary Heart Disease: A Review.
JAMA Intern Med. 2022 Oct 1;182(10):1082-1088. doi: 10.1001/jamainternmed.2022.3171.
10
American Heart Association's Life's Simple 7: Lifestyle Recommendations, Polygenic Risk, and Lifetime Risk of Coronary Heart Disease.
Circulation. 2022 Mar 15;145(11):808-818. doi: 10.1161/CIRCULATIONAHA.121.053730. Epub 2022 Jan 31.

引用本文的文献

1
Inflammatory markers in pregnancy - identifying drivers in four large cohorts.
Front Immunol. 2025 Jun 9;16:1561798. doi: 10.3389/fimmu.2025.1561798. eCollection 2025.
2
Analysis of risk factors for PCI no-reflow in coronary heart disease and construction of related prediction models.
Am J Transl Res. 2024 Aug 15;16(8):3733-3741. doi: 10.62347/ECNI6080. eCollection 2024.

本文引用的文献

2
Polygenic risk scores for the prediction of cardiometabolic disease.
Eur Heart J. 2023 Jan 7;44(2):89-99. doi: 10.1093/eurheartj/ehac648.
4
Predictive Utility of a Validated Polygenic Risk Score for Long-Term Risk of Coronary Heart Disease in Young and Middle-Aged Adults.
Circulation. 2022 Aug 23;146(8):587-596. doi: 10.1161/CIRCULATIONAHA.121.058426. Epub 2022 Jul 26.
5
Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association.
Circulation. 2022 Aug 23;146(8):e93-e118. doi: 10.1161/CIR.0000000000001077. Epub 2022 Jul 18.
6
Development of a clinical polygenic risk score assay and reporting workflow.
Nat Med. 2022 May;28(5):1006-1013. doi: 10.1038/s41591-022-01767-6. Epub 2022 Apr 18.
8
American Heart Association's Life's Simple 7: Lifestyle Recommendations, Polygenic Risk, and Lifetime Risk of Coronary Heart Disease.
Circulation. 2022 Mar 15;145(11):808-818. doi: 10.1161/CIRCULATIONAHA.121.053730. Epub 2022 Jan 31.
10
Clinical utility of polygenic risk scores for coronary artery disease.
Nat Rev Cardiol. 2022 May;19(5):291-301. doi: 10.1038/s41569-021-00638-w. Epub 2021 Nov 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验